Romanian heart failure care under the microscope: are guidelines being followed?

NCT ID NCT07465679

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study looks at 500 adults in Romania with heart failure with reduced ejection fraction who are taking Entresto. Researchers will use existing medical records to see if patients are also receiving other recommended medications like beta-blockers and SGLT2 inhibitors. The goal is to understand how closely real-world treatment matches clinical guidelines.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sacubitril/valsartan (Entresto)
What this could lead to
If successful, this study could show where Romanian doctors are doing well or need help in following heart failure treatment guidelines, potentially improving patient care.
What could go wrong
This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to other countries or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis

    Bucharest, 020334, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.